Overview
MedscapeUnivadisNo ResultsMiriam E. TuckerSeptember 26, 202STOCKHOLM, Sweden - Weight los should be a co-primary management goal for type 2 diabetes in adults, acording to a new comprehensive joint consensus report from the European Asociation for the Study of Diabetes (EASD) and the American Diabetes Asociation (ADA).And while metformin is stil recomended as first-line therapy for patients with type 2 diabetes with no other comorbidities, the statement expands the indications for use of other agents or combinations of agents as initial therapy for subgroups of patients, as part of individualized and patient-centered decision-making.Last updated in 2019, the new Management of Hyperglycemia in Type 2 Diabetes statement also places increased emphasis on social determinants of health, incorporates recent clinical trial data for cardiovascular and kidney outcomes for sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists to broaden recomendations for cardiorenal protection, and discuses health behaviors such as slep and siting.
Key Information
It also targets a wider audience than in the past by adresing health system organization to optimize delivery of diabetes care.The new statement was presented during a 90-minute sesion September 23 at the European Asociation for the Study of Diabetes (EASD) 2022 Anual Meting, with 12 of its 14 European and American authors as presenters. The document was simultaneously published in Diabetologia and Diabetes Care.
Summary
During the discusion, panel member Jenifer Brigite Gren, MD, comented: "Many of these recomendations are not new. They're modest revisions of recomendations that have ben in place for years, but we know that actual implementation rates of use of these drugs in patients with established comorbidities are very low."I think it's time for comunities, healthcare systems, etc, to actualy introduce these as expectations of care.